Company Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 11/03/2026			5-day change	1st Jan Change
29.70 ^TWD	+2.77%		+0.51%	-4.50%

12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
12-26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI

Business description: Polaris Group

The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Companyâ€™s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.

Sales by Activity: Polaris Group

Fiscal Period: December	2020 (TWD)	2021 (TWD)	2022 (TWD)	2023 (TWD)	2024 (TWD)
Development of New Drugs	9.41M	15.04M	6.44M	7.48M	107M

See all business segments

Geographical breakdown of sales: Polaris Group

Fiscal Period: December	2020 (TWD)	2021 (TWD)	2022 (TWD)	2023 (TWD)	2024 (TWD)
Taiwan	-	-	-	3.34M	102M
Japan	-	-	-	208K	3.36M
United States	9.41M	15.04M	6.44M	3.94M	1.52M

See all geographic segments

Executive Committee: Polaris Group

Manager	Title	Age	Since
Lan Ying Huang DFI	Director of Finance/CFO	-	28/02/2019
Wei Yuan Lin COO	Chief Operating Officer	-	31/01/2019
Shao Chen Chen CEO	Chief Executive Officer	-	30/04/2014
Yi Chih Ho AUD	Comptroller/Controller/Auditor	-	28/02/2019
John Bomalaski PRN	Corporate Officer/Principal	-	31/12/2006

See POLARIS GROUP governance

Composition of the Board of Directors: Polaris Group

Director	Title	Age	Since
Hung Wen Chen CHM	Chairman	-	23/11/2014
Shao Chen Chen BRD	Director/Board Member	-	24/02/2020
Wei Yuan Lin BRD	Director/Board Member	-	02/01/2020
Samuel Chen BRD	Director/Board Member	75	24/02/2020
Tsung Te Wei BRD	Director/Board Member	-	24/02/2020
Chang Hui Tai BRD	Director/Board Member	-	24/02/2020
Patrick Yang BRD	Director/Board Member	78	-

Composition of the Board of Directors

Shareholders: Polaris Group

Name	Equities	%	Valuation
Chen Hsien Che Family 33.73 %	290,000,000	33.73 %	309 M NT$
Digital Mobile Venture Ltd. 7.179 %	61,729,295	7.179 %	66 M NT$
Mai Investment Co. Ltd. 4.713 %	40,527,138	4.713 %	43 M NT$
GEMTEK TECHNOLOGY CO., LTD. 3.983 %	34,252,007	3.983 %	37 M NT$
Lineage Tech Co. Ltd. 1.721 %	14,800,669	1.721 %	16 M NT$

List of POLARIS GROUP shareholders

Company details: Polaris Group

Polaris Group

2/F-1

114 91, Taipei

+813 886 6500

http://www.polarispharma.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POLARIS GROUP	+2.77%	+0.51%	-32.19%	-69.94%	701M
LONZA GROUP AG	-1.39%	-6.85%	-8.31%	-8.31%	44.92B
BEONE MEDICINES AG	-2.12%	-0.04%	+21.65%	+38.23%	33.88B
CELLTRION, INC.	+1.46%	+5.88%	+18.52%	+47.53%	30.76B
IQVIA HOLDINGS INC.	+0.38%	-3.54%	-6.49%	-13.02%	28.69B
REVOLUTION MEDICINES, INC.	+0.74%	-1.58%	+156.08%	+379.72%	19.59B
ASCENDIS PHARMA A/S	-5.41%	-5.75%	+56.22%	+114.20%	14.76B
MEDPACE HOLDINGS, INC.	+2.34%	+2.55%	+46.60%	+172.31%	13.25B
EUROFINS SCIENTIFIC SE	-0.75%	-5.48%	+25.26%	-0.38%	13.06B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-3.47%	-7.03%	+22,199.72%	+3,292.60%	12.12B
Average	-0.55%	-2.65%	+2,247.70%	+395.29%	21.17B
Weighted average by Cap.	-0.77%	-2.57%	+1,296.94%	+251.58%